Citius Oncology Successfully Closes $9 Million Public Offering for LYMPHIR Commercialization

Citius Oncology, Inc. (Nasdaq: CTOR), a prominent player in the field of oncology therapeutics and a majority-owned subsidiary of Citius Pharmaceuticals, announced the successful closing of its public offering on July 17, 2025. This offering raised approximately $9 million through the sale of 6,818,182 shares of common stock at a public offering price of $1.32 per share. Additionally, the offering included warrants for future stock purchases under the same terms, with an exercise price of $1.32 per share.

The gross proceeds from this deal will be crucial for Citius Oncology as they aim to enhance the commercialization efforts of their flagship product, LYMPHIR. This drug is designed to target cutaneous T-cell lymphoma (CTCL), a type of skin cancer, and has already garnered FDA approval for adults who have had at least one previous systemic therapy. The demand for LYMPHIR is expected to exceed $400 million in its initial market, highlighting a significant opportunity for the company.

The company stated that the net proceeds from the offering will principally be allocated towards various strategic initiatives. These include meeting milestone and royalty obligations as outlined in existing licensing agreements and providing working capital to support ongoing corporate needs. Maxim Group LLC acted as the sole placement agent for this offering, ensuring that the funds are secured to propel the company forward.

Citius Oncology’s commitment to innovation is strongly supported by robust intellectual property protections, which encompass orphan drug designation, advanced technology, and pending patents that can be paired with existing immuno-oncology therapies. These attributes position Citius Oncology favorably in a competitive healthcare landscape.

The public offering is part of a broader strategic plan that includes engaging with potential partners for distribution agreements, thereby expanding the reach of LYMPHIR into markets that remain underserved by current treatments. Management has emphasized the urgency of making LYMPHIR more accessible to patients who are in dire need of effective therapies due to limited options thus far.

Citius Pharmaceuticals, the parent company, also plays a pivotal role in ensuring that its subsidiaries have access to the resources they need for successful product development and market introduction. Apart from LYMPHIR, Citius Pharmaceuticals is progressing on additional late-stage product candidates, including Mino-Lok®, a catheter care solution, which further demonstrates their dedication to addressing critical healthcare challenges with innovative solutions.

The company's leadership has expressed optimism about the future, underscoring its solid pipeline and the expected impact on the quality of life for targeted patient populations. However, they also acknowledge the various external challenges, including market dynamics and regulatory landscapes, that could affect the company’s growth trajectory. The management team is actively mapping out plans for ongoing compliance with Nasdaq listing requirements as they navigate through these challenges.

In conclusion, the successful closing of the $9 million public offering represents a significant milestone in Citius Oncology’s journey. With the targeted allocation of funds to support LYMPHIR's commercialization, the company is poised to make strides in oncology care. Continuous efforts are in place to secure relationships with distribution partners, ensuring that patients will soon have better access to this much-needed treatment option. For more information about Citius Oncology and its offerings, visit Citius Oncology Website.

This press release should not be construed as an offer to sell or solicit any of the securities mentioned herein. The securities were offered only through a prospectus that can be obtained from the relevant parties as detailed previously.